{
    "clinical_study": {
        "@rank": "57175", 
        "arm_group": {
            "arm_group_label": "Dacomitinib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "As part of the global clinical development program for Dacomitinib, studies are planned in\n      cancer patients in China. An assessment of Dacomitinib pharmacokinetics in Chinese subjects,\n      as required by the Chinese Health Authorities, is therefore warranted.\n\n      The single 45 mg oral dose pharmacokinetics of Dacomitinib will be characterized."
        }, 
        "brief_title": "Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "To evaluate the pharmacokinetics of Dacomitinib in Chinese healthy volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Chinese volunteers (individuals currently residing in mainland China, who\n             were born in China, and whose parents are both of Chinese descent).\n\n          -  Healthy male and/or female (of non-childbearing potential) subjects between the ages\n             of 18 and 45 years, inclusive. (Healthy is defined as no clinically relevant\n             abnormalities identified by a detailed medical history, full physical examination,\n             including blood pressure and pulse rate measurement, 12-lead ECG or clinical\n             laboratory tests).\n\n          -  Body Mass Index (BMI) of 19.0 to 24.0 kg/m2; and a total body weight should be 50 kg\n             (110 lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant dermatologic, hematological, renal,\n             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,\n             neurologic, or allergic disease (including drug allergies, but excluding untreated,\n             asymptomatic, seasonal allergies at the time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  Drug dependency, a positive urine drug screen and/or alcohol dependency.\n\n          -  Use of tobacco- or nicotine- containing products (or a positive urine cotinine test).\n\n          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14\n             drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of\n             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.\n\n          -  Treatment with an investigational drug or biologic within the last 3 months (or as\n             determined by the local requirement) or 5 half-lives preceding the first dose of\n             study medication, whichever is longer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097433", 
            "org_study_id": "A7471051"
        }, 
        "intervention": {
            "arm_group_label": "Dacomitinib", 
            "description": "A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers", 
            "intervention_name": "Dacomitinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Dacomitinib", 
            "PF299804", 
            "pharmacokinetics", 
            "healthy", 
            "Chinese"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7471051&StudyName=Dacomitinib%20%28PF-00299804%29%20Pharmacokinetics%20In%20Chinese%20Healthy%20Volunteers"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Open-label Study To Characterize The Pharmacokinetics Of A Single 45 Mg Oral Dose Of Dacomitinib (PF-00299804) In Healthy Chinese Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)of Dacomitinib", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05199265", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of PF-05199265", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)of PF-05199265", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]of PF-05199265", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)of PF-05199265", 
                "safety_issue": "No", 
                "time_frame": "predose, 1, 2 ,4, 6, 8, 12, 24, 48 ,72 ,96, 120, 144, 168, 192, 216, 240 ,264 hours post\u2010dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}